Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol

Name: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol
Start: 2030-07-01

July 1, 2030

Company: Tempest Therapeutics, Inc. (TPST)
Drug: tpst-1120
Indication: Hepatocellular Carcinoma (HCC)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol — TPST Phase 3 Readout | BioSniper